

Reference:	FOI.21334.26
Subject:	Asthma treatments
Date of Request:	14 August 2026

Requested:

How many new patients were treated for Asthma by the Trust's Respiratory Department in the latest 4 month period (April - July 2026) with the treatments I have provided below?

Please can you define a "new patient" as a patient who has received any of the treatments listed below for the first time. If a patient received any of the below treatments before the 1st August 2025, they can be classed as a new patient for the purposes of this question.

- Cinqaero (Reslizumab)
- Dupixent (Dupilumab)
- Fasenra (Benralizumab)
- Nucala (Mepolizumab)
- Tezpire (Tezepelumab)
- Xolair (Omalizumab)

Response:

Hywel Dda University Health Board (UHB) provides within the table overleaf, the number of new patients that were treated for Asthma with the listed medications by the Secondary Care Respiratory service, during the period 1 April to 31 July 2026.

Medication	Number
Cinqaero (Reslizumab)	0
Dupixent (Dupilumab)	0
Fasenra (Benralizumab)	9
Nucala (Mepolizumab)	0
Tezpire (Tezepelumab)	21
Xolair (Omalizumab)	0